Renaissance Technologies
CTXR icon

Renaissance Technologies’s Citius Pharmaceuticals CTXR Stock Holding History

Renaissance Technologies’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,571
Closed -$61K – 3799
2023
Q3 		$61K Sell
3,571
-9,476
-73% -$225K ﹤0.01% 3363
2023
Q2 		$391K Sell
13,047
-2,924
-18% -$96.2K ﹤0.01% 2999
2023
Q1 		$467K Sell
15,971
-396
-2% -$11.4K ﹤0.01% 2919
2022
Q4 		$323K Buy
16,367
+736
+5% +$20.1K ﹤0.01% 3188
2022
Q3 		$473K Buy
15,631
+412
+3% +$11.3K ﹤0.01% 2954
2022
Q2 		$350K Buy
15,219
+13,647
+868% +$374K ﹤0.01% 3364
2022
Q1 		$70K Buy
+1,572
New +$62.1K ﹤0.01% 3851
2021
Q4 		– Sell
-35,540
Closed -$1.8M – 3947
2021
Q3 		$1.8M Sell
35,540
-40,394
-53% -$2.03M ﹤0.01% 2168
2021
Q2 		$6.61M Buy
75,934
+36,370
+92% +$2.19M 0.01% 1455
2021
Q1 		$1.76M Buy
39,564
+38,713
+4,549% +$1.54M ﹤0.01% 2305
2020
Q4 		$22K Buy
+851
New +$22.2K ﹤0.01% 3338
2020
Q2 		– Sell
-3,692
Closed -$55K – 3489
2020
Q1 		$55K Buy
+3,692
New +$78K ﹤0.01% 3309
2019
Q3 		– Sell
-2,053
Closed -$50K – 3458
2019
Q2 		$50K Sell
2,053
-808
-28% -$23K ﹤0.01% 3456
2019
Q1 		$102K Sell
2,861
-184
-6% -$5.42K ﹤0.01% 3297
2018
Q4 		$79K Buy
3,045
+712
+31% +$24.4K ﹤0.01% 3257
2018
Q3 		$100K Buy
+2,333
New +$111K ﹤0.01% 3244

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies's CTXR Position: Q4 2023 in Review

Renaissance Technologies sold out of Citius Pharmaceuticals (CTXR) in Q4 2023, closing a stake of 3,571 shares — an estimated $61K sold.

Renaissance Technologies first reported a position in CTXR in Q3 2018 and held it in 16 quarters. The position peaked at $6.61M in Q2 2021. 74 funds tracked by Wall St. Rank hold CTXR as of Q4 2023.

  • Renaissance Technologies reported no remaining Citius Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Renaissance Technologies sold 3,571 Citius Pharmaceuticals shares in Q4 2023, an estimated $61K.
  • Renaissance Technologies first reported a position in Citius Pharmaceuticals in Q3 2018 and held it in 16 quarters.
  • Renaissance Technologies's Citius Pharmaceuticals position peaked at $6.61M in Q2 2021.
  • 74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2023.

Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.